

## CLAIMS:

1. A dry powder inhalation composition comprising,
  - (a) at least 0.25% (by weight of the composition) of an active ingredient with a particle size of less than 10 microns in diameter, and
  - (b) a pharmaceutically acceptable particulate carrier with a particle size of less than 250 microns in diameter.
2. The dry powder inhalation composition according to Claim 1, wherein the composition comprises less than 10% (by weight of the composition) of the active ingredient.
3. The dry powder inhalation composition according to Claim 1 or Claim 2, wherein the composition comprises from about 0.26 to about 1% (by weight of the composition) of the active ingredient.
4. The dry powder inhalation composition according to Claim 1, which comprises from about 0.265 to about 0.5% (by weight of the composition) of the active ingredient.
5. The dry powder inhalation composition according to Claims 1 or 4, wherein the carrier is lactose.
6. The dry powder inhalation composition according to Claims 1 or 4, wherein the active ingredient is formoterol or a pharmaceutically acceptable derivative thereof.
7. The dry powder inhalation composition according to Claims 1 or 4, wherein the active ingredient is formoterol or pharmaceutically acceptable derivative thereof.
8. A capsule containing from 1 to 25 mg of a dry powder inhalation composition according to Claims 1 or 4.
9. A MDPI comprising a reservoir containing the dry powder inhalation composition of Claim 1 or 4.
10. A method for the treatment of chronic obstructive pulmonary disease by the step of administering the dry powder inhalation composition of Claim 1 or 4.